GigaGen

GigaGen Aims to Provide the World’s First Recombinant Polyclonal Hyperimmune γ-Globulin. The company's drugs are composed of a new generation of highly efficient components, driven by experts' understanding of immune dysregulation, enabling researchers to access antibody discovery technologies that rapidly characterize every cell in complex immune systems, powering their chosen drug targets, and identifying candidate drugs and conducting preclinical evaluations of efficacy.